Eventide Asset Management’s Obsidian Therapeutics OBX Stock Holding History

Eventide Asset Management’s Portfolio OBX Stock Details OBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.09M	Buy	+624,972	New	+$12.2M	0.13%	159

Other funds holding OBX

Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $150M AUM 39.16% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Eventide Asset Management's OBX Position: Q3 2026 in Review

Eventide Asset Management opened a new position in Obsidian Therapeutics (OBX) in Q3 2026: 624,972 shares worth $9.09M. The stake represents 0.13% of the portfolio and ranks #159 among its holdings.

26 funds tracked by Wall St. Rank hold OBX as of Q3 2026.

Eventide Asset Management held 624,972 shares of Obsidian Therapeutics worth $9.09M as of Q3 2026.
Obsidian Therapeutics was a new Eventide Asset Management position in Q3 2026.
Obsidian Therapeutics made up 0.13% of Eventide Asset Management's portfolio in Q3 2026, its #159 holding.
26 funds tracked by Wall St. Rank held Obsidian Therapeutics as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.